6-month data from first-in-human trials shows promise for bimatoprost-eluting IOL
February 3rd 2023Glaucoma 360
SpyGlass Pharma presented new data at the Glaucoma 360 New Horizons Forum that supports the use of their proprietary drug delivery platform to lower IOP in patients with glaucoma or ocular hypertension.
International Keratoconus Academy Symposium: What to expect
February 2nd 2023International Keratoconus Academy
CEO and cofounder of the International Keratoconus Academy S. Barry Eiden, OD, FAAO, FSLS, sits down to discuss the inaugural symposium, which will be held April 22-23, 2023, in Scottsdale, Arizona.
Ep. 2: EyeCon 2022: Come for the speakers, stay for the sun
October 10th 2022EyeCon
Optometry Times®' EyeCon 2022 co-chairs Kelly K. Nichols, OD, MPH, PhD, FAAO, and A. Paul Chous, MA, OD, FAAO, sat down with Ben Casella, OD, FAAO, chief optometric editor for Optometry Times® to chat all-things EyeCon 2022.
Ep. 1: EyeCon 2022: Join the fun in-person at Marco Island
September 28th 2022EyeCon
Optometry Times®' EyeCon 2022 co-chairs Kelly K. Nichols, OD, MPH, PhD, FAAO, and A. Paul Chous, MA, OD, FAAO, sat down with Ben Casella, OD, FAAO, chief optometric editor for Optometry Times® to chat all-things EyeCon 2022.
Medical management of glaucoma: Moving on down the road
September 16th 2022Vision Expo West
Optometrists are seeing recent advances in topical therapies that entered the market following decades of reliance of traditional single-agent drops. An implantable device that facilitates the slow release of drug is changing the landscape in glaucoma therapy.
VEW 2022: New dark adaptation modality and other pipeline updates from Heru
September 15th 2022Vision Expo West
Brandon Barber, chief marketing officer at Heru, shares about the company's new dark adaptation modality, which they announced during the 2022 Vision Expo West, as well as other advancements in the pipeline.